Table 2. Prognostic factors associated with in-hospital mortality.
| Univariate analysis | |||
|---|---|---|---|
| Variables | OR | 95% CI | P |
| Age | 1.043 | 1.019–1.068 | <0.000 |
| Male | 0.717 | 0.383–1.343 | 0.299 |
| IC group with HIV | 0.175 | 0.058–0.531 | 0.002 |
| IC group without HIV | 1.783 | 0.863–3.684 | 0.118 |
| Non-IC group | 3.191 | 0.963–10.570 | 0.058 |
| Cardiovascular disease | 1.195 | 0.452–3.159 | 0.720 |
| Interstitial lung disease | 0.138 | 0.030–0.640 | 0.011 |
| Dyspnea | 2.803 | 1.526–5.148 | 0.001 |
| C-reactive protein | 1.001 | 0.990–1.011 | 0.870 |
| AaDO2 | 1.003 | 1.001–1.005 | 0.007 |
| P/F ratio | 0.988 | 0.980–0.997 | 0.006 |
| Lactate dehydrogenase | 1.000 | 1.000–1.000 | 0.831 |
| Interval between admission and anti-PCP treatment | 1.044 | 0.978–1.116 | 0.195 |
| Multivariate analysis | |||
| Variables | OR | 95% CI | P |
| Age | 1.060 | 1.024–1.104 | 0.001 |
| AaDO2 | 1.002 | 1.000–0.005 | 0.016 |
| Dyspnea | 3.625 | 1.052–12.489 | 0.041 |
AaDO2, alveolar-arterial oxygen pressure difference; CI, confidence interval; HIV, human immunodeficiency virus; IC, immunocompromised; OR, odds ratio; PCP, Pneumocystis jirovecii pneumonia; P/F, PaO2/FiO2.